These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 1536960)

  • 21. Frequency and causes of refractoriness in multiply transfused patients.
    Legler TJ; Fischer I; Dittmann J; Simson G; Lynen R; Humpe A; Riggert J; Schleyer E; Kern W; Hiddemann W; Köhler M
    Ann Hematol; 1997 Apr; 74(4):185-9. PubMed ID: 9174547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Indirect allorecognition of platelets by T helper cells during platelet transfusions correlates with anti-major histocompatibility complex antibody and cytotoxic T lymphocyte formation.
    Semple JW; Speck ER; Milev YP; Blanchette V; Freedman J
    Blood; 1995 Jul; 86(2):805-12. PubMed ID: 7606011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusions.
    Heddle NM; Blajchman MA
    Blood; 1995 Feb; 85(3):603-6. PubMed ID: 7833464
    [No Abstract]   [Full Text] [Related]  

  • 24. Alloimmune refractoriness to platelet transfusions.
    Sandler SG
    Curr Opin Hematol; 1997 Nov; 4(6):470-3. PubMed ID: 9359008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathogen reduction with amotosalen/UVA reduces platelet refractoriness in a dog platelet transfusion model.
    Slichter SJ; Bailey SL; Gettinger I; Pellham E; Christoffel T; Castro G; Green JM; Stassinopoulos A
    Vox Sang; 2019 Aug; 114(6):595-604. PubMed ID: 31297836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leucocyte and platelet-derived bioactive substances in stored blood: effect of prestorage leucocyte filtration.
    Nielsen HJ; Skov F; Dybkjaer E; Reimert CM; Pedersen AN; Brünner N; Skov PS
    Eur J Haematol; 1997 Apr; 58(4):273-8. PubMed ID: 9186539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HPA antibodies in Algerian multitransfused patients: Prevalence and involvement in platelet refractoriness.
    Brouk H; Bertrand G; Zitouni S; Djenouni A; Martageix C; Griffi F; Kaplan C; Ouelaa H
    Transfus Apher Sci; 2015 Jun; 52(3):295-9. PubMed ID: 25620758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravascular and total body platelet equilibrium in healthy volunteers and in thrombocytopenic patients transfused with single donor platelets.
    Brubaker DB; Marcus C; Holmes E
    Am J Hematol; 1998 Jul; 58(3):165-76. PubMed ID: 9662266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical applications of leukocyte filters].
    Bordin JO; Fabron Júnior A
    Rev Assoc Med Bras (1992); 1997; 43(3):205-8. PubMed ID: 9497547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preparation of random donor leukocyte-poor platelets by cytapheresis.
    Olthuis HP; Stienstra S; Puylaert CE; Verhagen CM; Bär BM
    Transfus Sci; 1993 Apr; 14(2):195-7. PubMed ID: 10148612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of patients refractory to platelet transfusion.
    Chockalingam P; Sacher RA
    J Infus Nurs; 2007; 30(4):220-5. PubMed ID: 17667077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alloimmunization to platelets in heavily transfused patients with sickle cell disease.
    Friedman DF; Lukas MB; Jawad A; Larson PJ; Ohene-Frempong K; Manno CS
    Blood; 1996 Oct; 88(8):3216-22. PubMed ID: 8874223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of pooled platelet concentrates using prestorage versus poststorage WBC reduction: impact of filtration timing.
    Ferrer F; Rivera J; Corral J; Gonzalez-Conejero R; Lozano ML; Vicente V
    Transfusion; 2000 Jul; 40(7):781-8. PubMed ID: 10924604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of alloantigens and storage-associated factors on stimulated cytokine response in an in vitro model of blood transfusion.
    Biedler AE; Schneider SO; Seyfert U; Rensing H; Grenner S; Girndt M; Bauer I; Bauer M
    Anesthesiology; 2002 Nov; 97(5):1102-9. PubMed ID: 12411792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amotosalen: Allogeneic Cellular Immunotherapies system, INTERCEPT Plasma System, INTERCEPT Platelet System, S 59.
    BioDrugs; 2003; 17(1):66-8. PubMed ID: 12534321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of refractoriness and HLA-alloimmunization using filtered blood products.
    Sniecinski I; O'Donnell MR; Nowicki B; Hill LR
    Blood; 1988 May; 71(5):1402-7. PubMed ID: 3282572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Flow cytometric analysis of residual white blood cell concentration and platelet activation antigens in double filtered platelet concentrates.
    Lombardo JF; Cusack NA; Rajagopalan C; Sangaline RJ; Ambruso DR
    J Lab Clin Med; 1993 Nov; 122(5):557-66. PubMed ID: 8228574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
    Jia Y; Li W; Liu N; Zhang K; Gong Z; Li D; Wang L; Wang D; Jing Y; Wang J; Shan X
    Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of platelets and other transfusion products in patients with malignancy.
    Bayer WL; Bodensteiner DC; Tilzer LL; Adams ME
    Semin Thromb Hemost; 1992; 18(4):380-91. PubMed ID: 1470926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
    Basire A; Picard C
    Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.